Table 4 Trials evaluating preoperative anti-angiogenic treatment and RT in STS
Author | Evaluated patients | Treatment regimen | Tumor site | Patients with toxicity (CTCAE) ≥ grade 3 | Type of toxicity (CTCAE) ≥ grade 3 | Path. response: ≥ 90 % non-viable tissue |
|---|---|---|---|---|---|---|
Haas 2015 | 11 | Pazopanib/RT | Extremity (n = 11) | 3/11 | Hepatotoxicity | 4/10 |
Canter 2014 | 8 | Sorafenib/RT | Extremity (n = 8) | 4/8 | Skin rash (n = 2), anemia, perirectal abscess, supraventricular tachycardia | 3/8 |
Yoon 2011 | 20 | Bevacizumab/RT | Extremity (n = 13) Retro (n = 6) Trunk (n = 1) | 4/20 | Hepatotoxicity, hypertension | 7/20 |
Lewin 2014 | 9 | Sunitinib/RT | Extremity (n = 9) | 7/9 | Hepatotoxicity, hematotoxicity, hyponatremia, hyperglycemia, skin rash | Not reported |
Jakob 2015 | 16 | Sunitinib/RT | Extremity (n = 5) Retro (n = 10) Trunk (n = 1) | 8/16 | Hematotoxicity, hand-foot-syndrome | 5/16 |
Sunrase (this trial) | 9 | Sunitinib/RT | Extremity (n = 3) Retro (n = 4) Trunk (n = 2) | 5/9 | Hematotoxicity | 3/9 |
Sunyach 2014 | 10 | Sunitinib/RT | Extremity (n = 10) | Only DLT reported | Thrombopenia grade 4 (n = 1), no other dose limiting toxicity | Not applicable, therapy given for unresectable tumors |